Status:
COMPLETED
CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This observational study is restricted to postmenopausal women with hormone-sensitive early breast cancer, who have decided to take prescribed adjuvant use of AIs, anastrozole or letrozole, according ...
Eligibility Criteria
Inclusion
- Postmenopausal woman with hormone sensitive early breast cancer
- Documented decision of treatment with upfront adjuvant AI (either anastrozole or letrozole) according to current SmPC OR current treatment with AI (either anastrozole or letrozole) according to current SmPC, that has not exceeded thirteen weeks
Exclusion
- Upfront adjuvant AI medication which has exceeded thirteen weeks at randomisation
- Concomitant adjuvant treatment with tamoxifen or exemestane
- Previous use of adjuvant tamoxifen or exemestane exceeding thirteen weeks
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2011
Estimated Enrollment :
2600 Patients enrolled
Trial Details
Trial ID
NCT00681122
Start Date
May 1 2008
End Date
May 1 2011
Last Update
January 18 2016
Active Locations (164)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Canberra, Australian Capital Territory, Australia
2
Research Site
Coffs Harbour, New South Wales, Australia
3
Research Site
Newcastle, New South Wales, Australia
4
Research Site
Port Macquarie, New South Wales, Australia